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7RESEARCH ARTICLE Open AccessEfficacy of a live attenuated vaccine in
classical swine fever virus postnatally
persistently infected pigs
Sara Muñoz-González1, Marta Perez-Simó1, Marta Muñoz1, José Alejandro Bohorquez1, Rosa Rosell1,2,
Artur Summerfield3, Mariano Domingo1,4, Nicolas Ruggli3 and Llilianne Ganges1*Abstract
Classical swine fever (CSF) causes major losses in pig farming, with various degrees of disease severity. Efficient live
attenuated vaccines against classical swine fever virus (CSFV) are used routinely in endemic countries. However,
despite intensive vaccination programs in these areas for more than 20 years, CSF has not been eradicated.
Molecular epidemiology studies in these regions suggests that the virus circulating in the field has evolved under
the positive selection pressure exerted by the immune response to the vaccine, leading to new attenuated viral
variants. Recent work by our group demonstrated that a high proportion of persistently infected piglets can be
generated by early postnatal infection with low and moderately virulent CSFV strains. Here, we studied the immune
response to a hog cholera lapinised virus vaccine (HCLV), C-strain, in six-week-old persistently infected pigs following
post-natal infection. CSFV-negative pigs were vaccinated as controls. The humoral and interferon gamma responses as
well as the CSFV RNA loads were monitored for 21 days post-vaccination. No vaccine viral RNA was detected in the
serum samples and tonsils from CSFV postnatally persistently infected pigs for 21 days post-vaccination. Furthermore,
no E2-specific antibody response or neutralising antibody titres were shown in CSFV persistently infected vaccinated
animals. Likewise, no of IFN-gamma producing cell response against CSFV or PHA was observed. To our knowledge,
this is the first report demonstrating the absence of a response to vaccination in CSFV persistently infected pigs.Introduction
Classical swine fever (CSF) is one of the most devastating
diseases for the pig industry throughout the world affecting
both domestic pigs and wild boars [1,2]. It is endemic in
Asia, areas of Central and South America and in many
Eastern European countries [3,4] with sporadic occurrence
in Western Europe. The CSF virus (CSFV), the etiological
agent of CSF, is an icosahedral and enveloped positive
stranded RNA virus that, together with bovine viral
diarrhoea virus (BVDV) and border diseases virus, belongs
to the Pestivirus genus of the Flaviviridae family [5].
As with many other diseases affecting livestock, the
most efficient vaccines currently available against CSFV
are live attenuated and were developed over 50 years ago
[4,6]. The HCLV vaccine was developed in China, by* Correspondence: llilianne.ganges@cresa.uab.es
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creativecommons.org/publicdomain/zero/1.0/passage in rabbits. Because of its high efficacy and safety,
the HCLV vaccine was introduced into many other
countries and became known as the Chinese vaccine
strain (C-strain) [7]. Immune responses elicited by these
vaccines do not allow differentiating infected from vacci-
nated animals (DIVA). However, live attenuated vaccines
are still used in endemic countries. Furthermore, although
intensive control programs have been implemented for
over 20 years, the virus is still circulating in these regions;
therefore, the disease has not been eradicated. Various
degrees of CSF severity can be observed, ranging from
acute to chronic or subclinical forms.
Recent molecular epidemiology studies from some
endemic countries suggest that the virus circulating
in the field has evolved under the positive selection
pressure exerted by the immune response to the vaccine,
leading to new attenuated viral variants that reproduce
milder forms of CSF disease [3,8]. On the other hand,
moderate virulence strains were found throughout Europe,Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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2001–2002 CSFV outbreak in Spain that caused mild and
nonspecific clinical signs of CSF, an outbreak that was con-
trolled using a non-vaccination policy by stamping-out
strategy [9,10].
Recent work by our group demonstrated that persistently
infected piglets can be generated by early postnatal
infection with CSFV of low and moderate virulence
[11]. For six weeks after postnatal infection, most of
the piglets remained clinically healthy, despite persist-
ent high virus titres in the serum, tissues, nasal and
rectal swabs. Notably, these animals were unable to
mount any detectable humoral and cellular immune
response. At necropsy, the most prominent gross patho-
logical lesion was severe thymus atrophy. Contrary to per-
sistent infection, animals developing the chronic form of
CSF are able to generate a specific immune response
against the virus, mainly an antibody response [4,12,13].
Considering the CSF epidemiological situation in
endemic areas, where low virulence strains are prevalent
[3,4,8,14,15] and the epidemiological implications that
persistently infected animals can exert in the eradication
of the disease (revised in [16,17]) we studied the im-
mune response to a live attenuated CSFV vaccine in
six-week-old CSFV postnatally persistently infected pigs.
Interestingly, none of the vaccinated persistently infected
piglets developed a detectable immune response after vac-
cination. In addition, a complete lack of viral RNA was
detected in the serum samples and tonsils from CSFV
postnatally persistently infected pigs during the 21 days
post-vaccination (dpv). These results have important
implications for vaccine control programs in the endemic
context.
Materials and methods
Cells and viruses
PK-15 cells (ATCC CCL 33) were cultured in DMEM
medium, supplemented with 10% pestivirus-free foetal
bovine serum (FBS) at 37 °C in 5% CO2. The cells were
infected with 0.1 TCID50/cell in 2% FBS, and the virus was
harvested 48 h later. Peroxidase-linked assay (PLA) [18]
was used for viral titration following the statistical methods
described by Reed and Muench [19]. The Catalonia 01
strain belongs to the CSFV 2.3 genogroup [3], was isolated
from CSF Spanish epizootic in 2000–2001 [9,10] and was
the strain that originated the persistently infected pigs used
in this study [11]. The HCLV vaccine (C-strain) belongs to
CSFV 1.1 genogroup and was used in Spain in the 1980s
for CSF control. This vaccine has 100% homology with the
Z46258 strain into the Npro region [7]. Finally, the Thiverval
vaccine strain (provided by Pasteur Institute, Romania) was
used as the stimulus in the Elispot assay for detecting
CSFV-specific interferon-gamma (IFN-γ) producing cells.
This strain belongs to the CSFV 1.1 genogroup [20].Experimental design
To elucidate the immune response induced by the HCLV
vaccine (C-strain) in postnatally CSFV persistently infected
pigs, two groups with four domestic pigs each at six weeks
old were vaccinated with a pig dose (equivalent with 100
Protective Doses (PD) by intramuscular injection in the
neck. Group 1 included four CSFV postnatally persistently
infected pigs born in a biosafety level 3 (BSL3) animal
facility (CReSA, Barcelona, Spain) [11], numbered from 1
to 4. These pigs, which had been intranasally infected in
the first 8 h after birth with the CSFV Catalonia 01 strain,
were viraemic and apparently healthy at six weeks old
(study time), although they lacked a humoral response [11].
The second group (Group 2), housed in an independent
isolation unit at the BSL-3 facility of CReSA, consisted of
four pigs (numbered 5–8) from a sow of the same origin
as Group 1. Group 2 was free from Pestivirus, porcine
circovirus type 2 and porcine reproductive respiratory
syndrome virus. Both groups had an average weight of
12.6 kg per pig.
Serum, whole blood samples, nasal and rectal swabs
were taken at 0, 4, 8, 13, 15 and 21 dpv. The tonsils
were collected at the time of necropsy (21 dpv). The
experiments were approved by the Ethics Committee
for Animal Experiments of the Autonomous University
of Barcelona (UAB) according to existing national and
European regulations.
Clinical signs evaluation after vaccination
A trained veterinarian recorded rectal temperature and
clinical signs daily in a blinded manner. The pigs were
scored daily as follows: one point: pyrexia; two points:
pyrexia +mild clinical signs; three points: severe clinical
signs; and four points: death. After euthanasia (with
intravenous pentobarbital sodium injection), animals
were subjected to an exhaustive necropsy in which
pathological signs in different organs and tissues were
evaluated.
PBMCs collection and performing the ELISPOT assay for
the detection of CSFV-specific IFN-γ producing cells
Blood collected in 5 mM EDTA at 15 dpv was used to
obtain peripheral blood mononuclear cells (PBMCs) by
density-gradient centrifugation with Histopaque 1077
(Sigma). The total number of recovered live PBMCs was
obtained by staining with trypan blue [21]. The Elispot
assay to detect CSFV-specific IFN-γ cells was performed
as previously described by Tarradas et al. [22]. Briefly,
5 × 105 live PBMC/well were plated in duplicate at 0.1
multiplicity of infection (MOI) of CSFV Catalonia or
Thiverval strain at 0.01 MOI. As controls, duplicate of
cells were incubated in the presence of mock-stimulated
wells and Phytohaemagglutinin (PHA) (10 μg/mL). The
counts of spots in the media for mock-stimulated wells
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antigen-specific frequencies of IFN-γ producing cells.
CSFV neutralising and E2 specific antibodies detection
Serum samples taken at 0, 4, 8, 13, 15 and 21 dpv were
tested by performing a neutralisation peroxidase-linked
assay (NPLA) [23], and titres were expressed as the re-
ciprocal dilution of serum that neutralised 100 TCID50
of the Catalonia strain in 50% of the culture replicates.
The sera were also tested in the CSFV specific E2 ELISA
(HerdChek CSFV Ab, IDEXX); when the blocking per-
centage ≥40%, the samples were considered positive, fol-
lowing the manufacturer’s recommendations.
Detection of CSFV RNA
The RNA was extracted from all of the samples using
the viral RNA isolation kit Nucleospin II according to
the manufacturer's instructions (Macherey-Nagel). In all
cases, an initial volume of 150 μL was used to obtain a
final volume of 50 μL of RNA, which was stored at −80 °C.
The presence of CSFV Catalonia strain RNA was analysed
by RT-qPCR [24]. Positive results were considered for
threshold cycle values (CT) equal or less than 42. Samples
in which fluorescence was undetectable were considered
negative. Furthermore, the presence of vaccine virus
(C-strain) RNA was detected by RT-qPCR [7].
ELISA for IFN-α detection in serum samples from the
persistently infected-vaccinated group
To assess the innate immune response, serum IFN-α
levels in the persistently infected-vaccinated pigs wereFigure 1 Rectal temperature after vaccination. The individual rectal tem
attenuated vaccine (C-strain). Temperatures greater than 40 °C were consider
vaccinated pigs (Group 1: numbers 1 to 4) and Pestivirus-Free vaccinated pigsevaluated in serum samples at 0, 4, 8, 13 and 21 dpv.
Anti-IFN-α monoclonal antibodies (K9 and K17) and
IFN-α recombinant protein (PBL Biomedical Laboratories,
Piscataway, New Jersey, USA) were used in an ELISA
assay to detect IFN-α in serum samples [22,25-27].
The cut-off value was calculated as the average op-
tical density of negative controls (blank and negative
serums before CSFV infection) plus three standard
deviations. Cytokine concentrations in the serum
were determined using a regression line built with
the optical densities of the cytokine standards used
in the test.Results
Clinical signs after vaccination
After 21 dpv, no clinical signs were detected in vac-
cinated pigs from Group 2, and rectal temperatures
remained within the established normal range until
the end of the experiment, (Figure 1). Conversely,
the vaccinated CSFV persistently infected pigs showed
varying rectal temperature values; one of the pigs
showed fever from day 2 until day 15 post-vaccination
(pig #4), and had to be euthanized at 16 dpv after
developing hypothermia, as well as severe clinical
signs (diarrhoea, mild tremors, polyarthritis). Two
pigs (#2 and #3) developed fevers starting at day 17
and 21 post-vaccination, respectively, in the absence
of other clinical signs. Finally, pig #1 did not have an
increase in rectal temperature at any point in the
study with a healthy clinical status during the trial
(Figures 1 and 2).perature values were recorded daily after vaccination with a live
ed fevers (indicated with a black dotted bar). CSFV persistently infected-
(Group 2: numbers 5 to 8). † The pig was euthanized at 16 dpv.
Figure 2 Clinical score values in CSFV persistently infected-vaccinated pigs. The individual clinical signs were recorded daily after
vaccination until 21 days post-vaccination. The scores are defined in Section 2. † The pig was euthanized at 16 dpv.
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producing cells from the persistently infected-vaccinated
group
The ELISPOT assay results for the detection of IFN-γ in
PBMC from persistently infected pigs (Group 1) showed
a complete lack of response to stimulation against CSFV
(MOI = 0.1 and 0.01) and PHA after 15 dpv (Figure 3).
On the contrary, PBMC from vaccinated pigs in Group
2 showed a specific IFN-γ-producing cell response
against CSFV and (PHA) stimuli (Figure 3).
Absence of E2-specific antibodies and neutralising activity
after vaccination of the persistently infected pigs
To evaluate the induction of CSFV-specific antibodies,
serum samples were analysed at different times afterFigure 3 CSFV-specific IFN-γ producing cells at 15 dpv. CSFV persisten
Free vaccinated pigs (Group 2: numbers 5 to 8). Induction of CSFV-specific
and MOI = 0.01, respectively) and PHA.vaccination. All vaccinated pigs from Group 2 showed
E2-specific antibodies response detected by ELISA from
15 to 21 dpv (Figure 4A). Likewise, neutralising antibody
titres were detected at 15 and 21 dpv (Figure 4B). In con-
trast, an absence of antibody response, in terms of E2-
specific antibodies and neutralising titres, was found in all
CSFV persistently infected-vaccinated pigs (Group 1) dur-
ing the entire experiment (Figures 4A and B).
CSFV RNA detection in serum, nasal and rectal swabs
samples after vaccination
CSFV Catalonia strain-RNA was detectable in all of the
samples analysed from postnatally persistently infected
animals (Group 1) before vaccination until the end of the
trial. A high level of Catalonia strain RNA was detected intly infected-vaccinated pigs (Group 1: numbers 1 to 4) and Pestivirus-
IFN-γ producing cells against different stimuli: mock, CSFV (MOI = 0.1
Figure 4 E2-specific antibody detection and neutralising activity during 21 days post-vaccination. CSFV persistently infected-vaccinated
pigs (Group 1: numbers 1 to 4) and Pestivirus-Free vaccinated pigs (Group 2: numbers 5 to 8). A) Antibody response against the E2 glycoprotein
detected by ELISA (in blocking %) at 0, 4, 8, 13, 15 and 21 days post-vaccination. Values greater than 40% were considered positive
(indicated by a black dotted bar). B) Neutralising antibodies titres at 15 and 21 dpv. * This animal was euthanized at 16 dpv.
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amounts of Catalonia strain-RNA were detected in nasal
and rectal excretions, as well as in the tonsils. There was a
mostly constant amount of Catalonia strain RNA in serum
samples and nasal swabs after one week post-vaccination
(Figures 5A, B and C). In contrast, all vaccinated pigs from
Group 2 were CSFV Catalonia strain-RNA negative
throughout the experiment (data not shown).
Lack of vaccine virus RNA detection in postnatally
persistently infected pigs
CSFV vaccine virus RNA was detected in all of the
sera samples analysed at 4 and 8 dpv and also in the
tonsils from vaccinated pigs in Group 2. By contrast,
a lack of vaccine virus (C-strain) RNA was detected
in all of the samples tested from postnatally persistently
infected-vaccinated pigs, including in the tonsils (Group 1)
(Table 1).Lack of IFN-α detection in serum samples from
persistently infected-vaccinated group
In general, an absence of IFN-α was found in all of the
serum samples analysed both before (day 0) and after
vaccination from persistently infected-vaccinated pigs
(data not shown). In the case of vaccinated pigs from
Group 2, positive values were found only at 4 dpv ranged
up to 40 U/mL (Data not shown).
Discussion
It was shown over 40 years ago that congenital persistent
infection is the most important cause by which CSFV is
perpetuated in the domestic pig population [12]; however,
little is known about the mechanisms involved. Currently,
CSF causes significant losses in the pig farming industry
worldwide, and despite the intensive control programs
implemented in endemic countries for more than
20 years, the disease has not been eradicated in the world.
Figure 5 Catalonia strain RNA detection in serum, nasal and rectal swabs at different times after vaccination with Hoffman assay.
CSFV persistently infected-vaccinated pigs (Group 1: numbers 1 to 4). A) Catalonia strain RNA detection in serum samples from CSFV persistently infected-
vaccinated pigs at 0, 4, 8, 13, 15 and 21 dpv. B) Catalonia strain RNA detection in nasal swabs at 0, 4, 8, 15 and 21 dpv. C) Catalonia strain RNA detection in
rectal swabs at 0, 4, 8, 15 and 21 dpv. A dotted bar indicates the detection limit of the technique above 42 CT. * This animal was euthanized at 16 dpv.
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viral evolution studies conducted in some of these zones
that suggest the origin and circulation of low to moderate
virulence strains, and the role that these types of strains
may play as one important risk factor for the development
of CSFV persistence in pigs [3,8,14,15,28-31], the ex-
istence of CSFV persistently infected pigs in endemic
countries cannot be ruled out [16,17].Recent work by our group demonstrated that CSFV
persistently infected piglets can be generated by early post-
natal infection either with a low or a moderate virulence
CSFV strains [11].
Interestingly, the postnatally persistently infected animals
became viraemic, excreting high viral loads during the
six weeks of the study, but were unable to generate
either humoral or cellular immune responses against
Table 1 CSFV-vaccine RNA detection (C-strain) in serum at different times post-vaccination and in the tonsil samples
CT value in serum samples (Days post-vaccination) CT value in
tonsil samplesaGroup of pigs N° of pig 0 dpv 4 dpv 8 dpv 13 dpv 15 dpv 21 dpv
Persistently infected-vaccinated pigs
(Group 1)
1 Undetected Undetected Undetected Undetected Undetected Undetected Undetected
2 Undetected Undetected Undetected Undetected Undetected Undetected Undetected
3 Undetected Undetected Undetected Undetected Undetected Undetected Undetected
4b Undetected Undetected Undetected Undetected Undetected - Undetected
Pestivirus-Free vaccinated pigs
(Group 2)
5 Undetected 39,34 39,68 40,41 Undetected Undetected 26,27
6 Undetected 40,10 40,20 40,05 Undetected Undetected 26,07
7 Undetected 39,11 39,12 Undetected Undetected Undetected 26,52
8 Undetected 39,06 40,13 Undetected Undetected Undetected 28,32
a Tonsil samples collected after the necropsy (21 dpv).
b This animal was euthanized for ethical reasons at 16 dpv.
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response to a live attenuated vaccine (HCLV C-strain)
in six-week-old CSFV persistently infected pigs, con-
sidering that this type of vaccine is routinely used in
many of the endemic countries [3,7,8,32]. A complete
lack of the vaccine viral RNA was detected in the
serum samples and tonsils from CSFV postnatally persist-
ently infected pigs during 21 days post-vaccination. Previ-
ous studies have shown that the tonsil is considered a
target for the vaccine virus replication and wherein
the vaccine virus persists for more than 30 days post-
vaccination [4,33]. Furthermore, a lack of response to
E2-specific antibodies and an absence of neutralising
antibody titres were shown in CSFV persistently
infected-vaccinated animals. Likewise, an absence of
IFN-γ-producing cell response against CSFV or PHA
was also observed. Considering the role played by
IFN-γ in the control of CSFV infection [22,34], persistently
infected-vaccinated animals maintained an immunosup-
pressive state. Herein lies one of the main differences
between persistently and chronic infected pigs; in animals
suffering from chronic infection, a CSFV-specific immune
response is generated. Furthermore, the immunological
anergy developed in postnatally persistently infected pigs
supported the previously results described [11].
On the other hand, CSFV exacerbates the IFN-α
response, which is detected in the serum of infected
pigs; this response has been hypothesised to be related to
disease severity rather than to protective immune
responses [22,35]. Notwithstanding, IFN-α values were
undetectable in the sera from postnatally persistently
infected pigs after vaccination.
The absence of a CSFV-specific immune response
generated following immunisation could be related to
the apparent absence of replication of the vaccine virus in
the samples analysed from these animals. Immunological
tolerance has been described for CSF when the virus is
transmitted in utero, leading to a persistently infected
farrow [13]. Understandably, the pigs of this study(postnatally persistently infected), besides their immuno-
logical anergy [11], also might be immunotolerant. The
blocking of a CSFV-specific immune response generated
by the host should be beneficial for virus replication [36],
as is the case for the CSFV Catalonia strain that induced
the persistence in these animals. Paradoxically, the vaccine
virus did not follow this logic, given the lack of viral detec-
tion in samples analysed after the vaccination of postnatally
persistently infected pigs. Perhaps, the high viral load
generated by the strain that induced the persistent infec-
tion (Catalonia strain) may be preventing the vaccine virus
replication in the target tissues, changing or avoiding its
replication capacity. Previous studies conducted in cell cul-
tures with BVDV demonstrated that cells acutely infected
with this virus were protected from the second infection
by a homologous BVDV [36]. Probably, this interference
phenomenon previously described in BVDV and CSFV in
in vitro assays, would explain the lack of vaccine virus
(C-strain) RNA detection in the samples analysed
after the vaccination of postnatally persistently infected
pigs, since the RNA from the vaccine strain could not
enter into the host cells [37,38]. On the contrary and as
expected, all vaccinated pigs in Group 2 were able to
mount efficient humoral and cellular responses between
15 and 21 dpv [4,9,16,22,34], which can be associated with
the RNA vaccine virus detection in the tonsil from these
pigs. The efficacy of the C-strain vaccine in preventing clin-
ical CSF seems to approach 100%. Most data from pre-
vious studies indicate a very high level of protection
against the development of clinical signs after challenge,
irrespective of the challenge strains used, even if the
strains are from different CSFV genotypes [34,39-43].
Additionally, the C-strain vaccine (1.1 genotype) induced
a detectable humoral response to CSFV [4,16].
The persistently infected-vaccinated pigs maintained
high viral loads only for the CSFV Catalonia strain in
serum throughout the study, and also had high amounts
of viral RNA of this strain in nasal and rectal excretions.
There was a constant amount of viral RNA in serum
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as the high amount of viral excretion and the inability
to induce a specific immune response, are common
characteristics of Pestivirus-persistently infected animals
[44]. However, contrary to CSFV postnatally persistently
infected pigs, calves persistently infected with BVDV are
able to develop immune responses against different patho-
gens, as well as respond to vaccination [45,46]. This fact
suggests a different relationship between CSFV and its
host despite both viruses being classified in the Pestivirus
genus. The underlying factors for the development of
clinical signs after a long period of incubation in persist-
ently infected animals are unknown [47]. The late onset of
disease has been described in this form, coursing with
depression, anorexia, elevated temperature, conjunctivitis,
dermatitis and locomotion disturbances [17]. Perhaps the
vaccination could be a trigger for the disease progression,
as would be the case for pig #4 (Figures 1 and 2). Before
vaccination, this pig remained apparently healthy, but
developed clinical signs (principally, fever peaks) two days
post-vaccination (Figure 1). Our findings pose a better
understanding of persistent infection with CSFV and
also emphasise the need for diagnostic tools that can
detect the existence of this CSF form in the field.
Furthermore, our work supports once again that the
vaccination strategies alone are not sufficient to eradicate
the disease [4].
Considering their high levels of viral excretion,
these animals can promote transmission to other
healthy pigs in the herd, especially in situations where
vaccination is not practiced or where the vaccination
program is inefficient. Then, they can cause the
short-cycle type of infection, which produces an acute
fatal disease with high mortality [12]. Epidemiologically,
it is not known how these pigs behave in the field, or
the role they play in maintaining the infection in
endemic countries, particularly important considering
a population of 1% of persistently infected calves can
maintain infection with BVDV in a farm [45]. There
is still much more to know about CSFV postnatal persist-
ent infection. Immunologically, we are only beginning
to discover the mechanisms underlying the establish-
ment of this form of disease; on a molecular level, it
is known to be associated only with low-moderate
virulence strains, but we still do not understand the
reason why.
To our knowledge, this is the first report demon-
strating the absence of a response to vaccination in
pigs persistently infected with CSFV for 21 days
post-vaccination. These results may have relevant im-
plications for CSF control by vaccination. Likewise,
these results might be of great value to understand the
response to other persistent viral infections in humans
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